Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer

Yuehan Wang*, Cécile M. Ronckers, Flora E. van Leeuwen, Chaya S. Moskowitz, Wendy Leisenring, Gregory T. Armstrong, Florent de Vathaire, Melissa M. Hudson, Claudia E. Kuehni, Michael A. Arnold, Charlotte Demoor-Goldschmidt, Daniel M. Green, Tara O. Henderson, Rebecca M. Howell, Matthew J. Ehrhardt, Joseph P. Neglia, Kevin C. Oeffinger, Helena J.H. van der Pal, Leslie L. Robison, Michael SchaapveldLucie M. Turcotte, Nicolas Waespe, Leontien C.M. Kremer, Jop C. Teepen, Flora E. van Leeuwen, Florent de Vathaire, Helena J.H. van der Pal, Nadia Haddy, Ibrahima Diallo, K. Scott Baker, Amy Berrington de González, Miriam R. Conces, Louis S. Constine, Mike Hawkins, Jacqueline J. Loonen, Marloes Louwerens, Geert O. Janssens, Lene Mellemkjaer, Raoul Reulen, Jeanette F. Winther

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology